The risk of relapse in the subgroup of progesterone-receptor-negative patients of breast tumors was five times greater for those with int-2/FGF3 amplification than for those without this alteration.627 High-throughput tissue microarray analysis showed that gene amplifications of FGF3 and FGF4 were observed in urinary bladder cancer.628 Kim and his colleagues629 revealed that three SNPs in the FGF23 gene (rs11063118, rs13312789, and rs7955866) were associated with an increased risk of prostate cancer. This evidence concerns the gene FGF23 and Familial prostate cancer.